Advanced EGFR-mutant NCSLC resistant to osimertinib therapy as a result of a novel CGN-RET fusion mutation with favorable response to combined osimertinib and selpercaptinib, case report
oleh: Hamid Mirshahidi, Sue Min Sophia Kwon, Alberto Romagnolo, Kiwon Park, Adam Hagele
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2023-09-01 |
Deskripsi
RET-fusions are a known cause of acquired osimertinib resistance in patients with advanced NSCLC. Herein we describe the case of a patient who developed resistance to osimertinib, via acquisition of a novel CGN-RET fusion mutation. She had a favorable response to treatment with RET-targeting TKI selpercatinib, in combination with osimertinib.